Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Eli Lilly and Company(LLY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low966.09
Day High991.22
Open:975.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Eli Lilly and Company

Select a category then submit the form to load news
Motley Fool
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
Motley Fool
Tariffs News & Market Chaos
Zacks Investment Research
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Tipranks
Eli Lilly’s TRANSCEND-T2D-1 Trial Completion: What Retatrutide Could Mean for LLY Investors
Tipranks
Eli Lilly’s Abemaciclib Combo Pushes Deeper Into Advanced Prostate Cancer
Tipranks
J.P. Morgan Keeps Their Buy Rating on Eli Lilly & Co (LLY)
Stock Target Advisor
Oil Price Surge Sinks Stocks-Market Analysis for March 5th, 2026
Oil Price Surge Sinks Stocks-Market Analysis: March 5th, 2026
Motley Fool
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
Tipranks
Lilly’s Tirzepatide Fasting Study Targets Safety Questions Around Obesity Blockbuster
Tipranks
Lilly Advances Remternetug Testing in China, Extending Its Alzheimer’s Pipeline Reach
Tipranks
Eli Lilly Advances New Oral Diabetes Drug In China: What Investors Should Watch
Tipranks
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Amgen (AMGN) and Eli Lilly & Co (LLY)
Motley Fool
2 Top Growth Stocks to Buy in the First Half of 2026
Motley Fool
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
Tipranks
Eli Lilly Expands Early-Stage Pipeline With New Phase 1 Study of LY4515100
Zacks Investment Research
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Newswire.ca
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Motley Fool
The Best Healthcare Stock to Invest $1,000 in Right Now
Motley Fool
Buying This 1 Pharmaceutical Stock Today Could Make You a Multimillionaire Retiree
Motley Fool
Why I'm Not Worried About Novo Nordisk Stock
Motley Fool
Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?
Zacks Investment Research
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Zacks Investment Research
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Motley Fool
Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?
Tipranks
Eli Lilly Advances Olomorasib With New Drug-Interaction Study, Quietly Building Long-Term Pipeline Value
Tipranks
Lilly’s Eloralintide Liver Study Signals Quiet but Steady Pipeline Momentum
Motley Fool
OPKO Health (OPK) Q4 2025 Earnings Call Transcript
Motley Fool
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
Motley Fool
Why Shares of Novo Nordisk Stock Sank (Again) This Week
Zacks Investment Research
ETFs to Buy as NVIDIA Shares Gain Following Q4 Earnings Beat
ETFs to Buy as NVIDIA Shares Gain Following Q4 Earnings Beat
Tipranks
Eli Lilly’s Oral Obesity Drug Trial Reaches Completion, Sharpening Investor Focus on LLY

Profile

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.